YS VS IXHL Stock Comparison

Performance

YS
10/100

YS returned -94.73% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

IXHL
10/100

IXHL returned -77.16% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

Volatility

YS
23/100

YS has had a lower than average amount of volatility over the last 12 months giving it a score of 22 of 100.

IXHL
38/100

IXHL has had a lower than average amount of volatility over the last 12 months giving it a score of 37 of 100.

Technicals

YS

"Technicals" not found for YS

IXHL
10/100

IXHL receives a 10 of 100 based on 14 indicators. 0 are bullish, 12 are bearish.

Profit

YS

"Profit" not found for YS

IXHL
10/100

Out of the last 20 quarters, IXHL has had 0 profitable quarters and has increased their profits year over year on 0 of them.

All score calculations are broken down here to help you make more informed investing decisions

YS Biopharma Co., Ltd. Ordinary Shares Summary

Nasdaq / YS

Healthcare

Biotechnology

YS Biopharma Co., Ltd., a biopharmaceutical company, engages in discovering, developing, manufacturing, and commercializing of vaccines and therapeutic biologics for infectious diseases and cancer. It develops a proprietary PIKA immunomodulating technology platform and a series of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, and Shingles. It operates in China, the United States, Singapore, the United Arab Emirates, and the Philippines. The company was founded in 2002 and is based in Beijing, China.

Incannex Healthcare Limited American Depositary Shares Summary

Nasdaq / IXHL

Healthcare

Drug Manufacturers - Specialty & Generic

Incannex Healthcare Limited engages in the research, development, and sale of medicinal cannabinoid products in Australia. It offers pharmaceutical grade cannabinoid products under the Incannex brand name. The company's products include IHL-42X, which is in Phase II clinical trials for obstructive sleep apnea; IHL-216A for traumatic brain injury; and IHL-675A, a combination of hydroxychloroquine and cannabidiol for the prevention and treatment of inflammatory lung conditions, such as acute respiratory distress syndrome, chronic obstructive pulmonary disease, asthma, and bronchitis, as well as rheumatoid arthritis and inflammatory bowel diseases. It has partnership with The Alfred Hospital and Novotech on IHL-42X clinical program for obstructive sleep apnea; and Monash Trauma Group at the Department of Neuroscience, Monash University to conduct a study on the protective effect of IHL-216A in sports concussion. The company was formerly known as Impression Healthcare Limited and changed its name to Incannex Healthcare Limited in June 2020. Incannex Healthcare Limited was incorporated in 2001 and is based in Sydney, Australia.

Power up your portfolio